CG Oncology在其Bond-003队列C临床研究中继续展现出同类疾病中最佳的持久性和耐受性表现。最新数据显示，在24个月的随访期内，该研究新增12名患者达到完全缓解状态，进一步证实了治疗方案的有效性和安全性。这一积极结果为CG Oncology的肿瘤治疗管线增添了更多信心，显示出其在肿瘤免疫治疗领域的领先地位。
CG Oncology在其Bond-003队列C临床研究中继续展现出同类疾病中最佳的持久性和耐受性表现。最新数据显示，在24个月的随访期内，该研究新增12名患者达到完全缓解状态，进一步证实了治疗方案的有效性和安全性。这一积极结果为CG Oncology的肿瘤治疗管线增添了更多信心，显示出其在肿瘤免疫治疗领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.